Key Developments: Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

7:49am EDT
Change (% chg)

kr.-1.00 (-0.30%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Bavarian Nordic A/S announces positive results from two pivotal clinical studies of Imvamune smallpox vaccine
Wednesday, 13 May 2015 01:36am EDT 

Bavarian Nordic A/S:Announces results from the first of two pivotal Phase 3 studies of the liquid-frozen formulation of Imvamune supporting a Biologics License Application for U.S. approval of the vaccine.Says in addition, the company announced results from a pivotal Phase 2 study of freeze-dried IMVAMUNE smallpox vaccine supporting the clinical requirements for an Emergency Use Authorization, which would allow for stockpiling of this next-generation of the vaccine.  Full Article

Bavarian Nordic A/S granted EUR 50 mln loan; upgrades expectations to year end cash preparedness
Tuesday, 12 May 2015 06:09am EDT 

Bavarian Nordic A/S:Says has been granted 50 million euros loan from The European Investment Bank (EIB).Announced securing of a loan facility of 50 million euros from European Investment Bank (EIB), long-term lending institution of European Union owned by its member states.EIB has granted loan facility to support research and development of novel vaccines against ebola and other infectious diseases as well as cancer immunotherapies.As a result of loan facility agreement, Co. upgrades its expectations to year-end cash preparedness from 1.10 billion Danish crowns to 1.45 billion crowns.  Full Article

Bavarian Nordic maintains FY 2015 financial expectations
Tuesday, 5 May 2015 01:41am EDT 

Bavarian Nordic A/S:Maintains its FY 2015 financial expectations with revenue at level of 1,000 million crowns and a break even result before interest and tax.Cash preparedness at year end is expected to be in level of 1,100 million crowns.  Full Article

Bavarian Nordic A/S gives FY 2015 guidance
Wednesday, 11 Mar 2015 02:38am EDT 

Bavarian Nordic A/S:For FY 2015 expects revenue at level of 1,000 million crowns / $144 million and a break even result before interest and tax (EBIT).Sees cash preparedness at year-end to be in level of 1,100 million crowns / $159 million.  Full Article

Bristol-Myers Squibb signs exclusive agreement with Bavarian Nordic A/S
Wednesday, 4 Mar 2015 01:30am EST 

Bavarian Nordic A/S and Bristol-Myers Squibb Company:Announced an agreement that provides Bristol-Myers Squibb an option to license and commercialize PROSTVAC.PROSTVAC is Bavarian Nordic's investigational Phase 3 prostate-specific antigen targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.Under terms of the agreement, Bavarian Nordic will receive an upfront payment of $60 million.Bristol-Myers Squibb can exercise the option in its sole discretion within a designated time after data is available from the ongoing Phase 3 trial.Bavarian Nordic would be entitled to a payment of $80 million upon exercise of the option plus additional incremental payments starting at $50 million, but with a potential to exceed $230 million should the median overall survival benefit of PROSTVAC exceed the efficacy seen in Phase 2 results.Furthermore, Bavarian Nordic could receive regulatory milestone payments of $110 million, up to $495 million in sales milestones as well as tiered double-digit royalties on future sales of PROSTVAC.The parties have also agreed to enter into a supply contract, under which Bavarian Nordic will undertake the future commercial manufacturing of PROSTVAC.  Full Article

A. J. Aamund A/S sells all shares in Bavarian Nordic A/S
Tuesday, 27 Jan 2015 01:57am EST 

Bavarian Nordic A/S:Says has received information from A. J. Aamund A/S that company has sold 1,793,944 shares in Bavarian Nordic and thus no longer holds any shares and voting rights in Bavarian Nordic.  Full Article

Bavarian Nordic announces initiation of phase 1 clinical trial for ebola vaccine regimen of MVA-BN Filo and Janssen's AdVac technology
Tuesday, 6 Jan 2015 02:10am EST 

Bavarian Nordic A/S:Announces initiation of phase 1 clinical trial for the ebola vaccine regimen of MVA-BN Filo and Janssen's AdVac technology.First human trial of MVA-BN Filo/AdVac preventative ebola vaccine regimen initiated in UK.Additional trials soon to be initiated in United States and Africa.Under the existing supply contract with Janssen, Bavarian Nordic has now produced 400,000 doses of its MVA-BN Filo component that form part of the prime boost vaccination regimen.First 400,000 doses will become available for use in large-scale clinical trials by April 2015.Expects 2 million doses from manufacturing under existing supply contract with Janssen, where it had previously expected 1 million doses.  Full Article

Bavarian Nordic A/S: first subject dosed with MVA-BN filo in phase 1 study of ebola candidate vaccines
Thursday, 4 Dec 2014 01:30am EST 

Bavarian Nordic A/S:Says announces first subject dosed with MVA-BN Filo in a Phase 1 study investigating a new prime-boost regimen of ebola candidate vaccines.  Full Article

Bavarian Nordic increases capital by exercise of warrants
Wednesday, 26 Nov 2014 05:19am EST 

Bavarian Nordic A/S:Says capital has been increased by nominally 1,046,500 Danish crowns as a consequence of exercise of warrants.Says after registration of capital increase share capital amounts to 276,712,470 Danish crowns.Says gross proceeds to Bavarian Nordic from capital increase amounts to 5,661,565 Danish crowns.Says exercise price for new shares is 54.1 Danish crowns per share of nominal 10 Danish crowns.Says new shares are expected to be admitted to trading and official listing on NASDAQ OMX Copenhagen on Nov. 27.Says content of announcement does not affect its expectations for 2014 financial results.  Full Article

Bavarian Nordic maintains FY 2014 revenue and EBIT guidance
Thursday, 13 Nov 2014 02:08am EST 

Bavarian Nordic A/S:Maintains expectations for FY 2014 financial results.Sees FY 2014 revenue at the level of 1,200 million Danish crowns and a break-even result before interest and tax (EBIT).  Full Article

Bavarian Nordic not for sale after big pharma deals

COPENHAGEN - Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters.

Search Stocks